3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
pembrolizumab
77
Carboplatin
74
Cisplatin
60
Paclitaxel
57
Magnetic Resonance Spectroscopy
55
Specimen Handling
54
Gemcitabine
47
Docetaxel
36
Dexamethasone
35
Fluorouracil
34
Bevacizumab
34
Pemetrexed
33
Oxaliplatin
33
Leucovorin
33
Doxorubicin
31
Radiotherapy
29
Radiation
29
Cyclophosphamide
29
Capecitabine
29
durvalumab
28
Rituximab
25
Letrozole
24
Irinotecan
24
Etoposide
24
Nivolumab
23
Vincristine
22
Lenalidomide
21
Taxes
20
Prednisone
20
Bortezomib
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Hizentra
×
30 days
×
Clear all
NCT07582432
2026-05-12
SIGMA
Grifols Biologicals, LLC
Phase 3
Recruiting
49 enrolled